Pharmacological treatment of TN secondary to MS is challenging owing to the poor tolerability of drugs and the lack of evidence-based information in the literature. There are no placebo-controlled studies, and the studies that do exist are small, open-label trials based on carbamazepine (CBZ), lamotrigine, gabapentin, topiramate, misoprostol or combination therapies [
32‐
43]. These case series reported potential efficacy of lamotrigine as monotherapy or associated with gabapentin or carbamazepine, topiramate and gabapentin. Pregabalin was tested in a pilot study investigating the effect on painful paroxysmal symptoms in sixteen patients with MS, including two patients with TN [
35]. Lamotrigine, with a mean dosage of 170 mg daily, significantly reduced pain related to TN in a group of 18 patients with MS [
33]. In a recent, prospective, open-label, pilot study five patients with TN secondary to MS were successfully treated by a combination treatment of pregabalin plus lamotrigine [
43]. The effect of topiramate was tested in six patients with MS and TN refractory to conventional medical therapy. Five out of six patients treated with topiramate (50–300 mg/day) reported complete pain relief [
36]. Three studies reported efficacy of misoprostol (a prostaglandin-E1-analogue) in a total of 28 patients with TN secondary to MS [
37,
44,
45]. Reder and Arnason reported that misoprostol (300–800 μg) relieved pain in six of seven patients who had failed to respond to conventional pharmacologic therapy, without serious side effects [
37]. DMKG study group tested the effect of misoprostol (600 μg) in refractory TN associated with MS. Eighteen patients completed the study period and 14 of them showed a reduction of more than 50% in attack frequency and intensity beginning five days after treatment onset. There were only mild and transient drug-related side effects in three patients [
45]. According to the international guidelines [
18], there is insufficient evidence to support or refute the effectiveness of any medication in treating pain in TN secondary to MS. It is, however, generally agreed that the first line therapy is pharmacological and is based, as it is for classical and idiopathic TN, on the use of sodium-channel blockers, i.e. CBZ and oxcarbazepine (OXC) [
46,
47]. These drugs block voltage-gated sodium-channels in a frequency-dependent manner and consequently reduce their action-potential firing frequency. Placebo-controlled trials in patients with classical and idiopathic TN demonstrated the efficacy of CBZ [
48,
49], with a number needed to treat to obtain important pain relief of 1.7–1.8 [
50]. However, this efficacy in classical and idiopathic TN is compromised by the tolerability, with a number needed to harm of 3.4 for minor adverse events and of 24 for severe adverse events [
51,
52]. The most frequent adverse effects involve the central nervous system, and include somnolence, dizziness and postural imbalance. OXC has a comparable efficacy to that of CBZ but a greater tolerability [
53] (except of the risk of hyponatremia) and a lower potential for drug interaction [
54,
55]. In TN secondary to MS, many patients never advance to the regimen required for pain relief because of intolerable adverse effects. CBZ and OXC can result in adverse effects that mimic a disease exacerbation, and the sudden onset or sudden worsening of common MS symptoms may, consequently, be erroneously treated with intravenous steroids [
32,
56]. As in classical and idiopathic TN, these drugs may be combined with lamotrigine, baclofen, pregabalin or gabapentin in patients that are unable to attain a full dosage of CBZ or OXC because of side effects [
57].
Patients suffering from persistent pain between the paroxysms are more resistant to CBZ and OXC [
57]. These drugs produce a frequency-dependent block of voltage-gated sodium channels and, thereby, by reducing the frequency of action potential firing, they effectively reduce paroxysmal pain; however, they have a far less positive effect on concomitant persistent pain. According to clinical experience, gabapentinoids and antidepressants might be more effective in persistent than in paroxysmal pain and are often tried as an add-on to OXC or CBZ in patients with the atypical form of TN with concomitant persistent pain [
57]. No trial, however, has directly assessed the efficacy of this combination in patients with persistent pain and there is no evidence to support or refute its use in clinical practice [
57].